Cannon Global Investment Management, LLC

Position in MDGL — Madrigal Pharmaceuticals, Inc.

CIK 1844427 DAVIE, FL

Back to MDGL Full portfolio

Position in MDGL

as of Mar 31, 2026 · filed Apr 21, 2026 Compact

Position Value

$418,776

+$11,138 QoQ

Shares Held

800

+14.3% QoQ

Ownership

0.003%

of shares outstanding

% of Portfolio

1.06%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2025

5 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in MDGL Over Time

Shares Held

Position Value (USD)

Derivatives in MDGL

reported options exposure · as of Mar 31, 2026

CallValue

$1,046,940

CallShares

2,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Cannon Global Investment Management, LLC holds $6,313,618 across 19 Biotechnology names. MDGL ranks #7 (6.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	8,500	$826,625
2	ALNY	Alnylam Pharmaceuticals, Inc.	2,400	$794,088
3	ABVX	Abivax S.A.	6,000	$668,100
4	TERN	Terns Pharmaceuticals, Inc.	9,000	$474,480
5	CTMX	CytomX Therapeutics, Inc.	96,100	$451,670
6	DNTH	Dianthus Therapeutics, Inc. /DE/	5,100	$427,992
7	MDGL	Madrigal Pharmaceuticals, Inc. This page	800	$418,776
8	RNA	Atrium Therapeutics, Inc.	25,087	$335,413

All Filings in MDGL

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,046,940	2,000	+150.0%	Call	Sole	2026-04-21
2026-03-31	$418,776	800	+14.3%	Shares	Sole	2026-04-21
2025-12-31	$407,638	700	-12.5%	Shares	Sole	2026-01-27
2025-09-30	$366,928	800	0.0%	Shares	Sole	2025-10-28
2025-06-30	$242,112	800	-46.7%	Shares	Sole	2025-07-29
2025-03-31	$496,845	1,500	—	Shares	Sole	2025-04-28
No filing history on record for this holder in this stock.